Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.

Core Points - The Greek Ministry of Health has approved VAZKEPA® (icosapent ethyl) for national reimbursement to reduce cardiovascular risk in high-risk adult patients treated with statins [1][2] - This approval represents the seventh national reimbursement of VAZKEPA® in Europe, enhancing access for eligible patients in Greece [2] - Vianex S.A. has been appointed as the exclusive distributor of VAZKEPA® in Greece, responsible for its import, registration, distribution, and commercialization [3][4] Company Overview - Amarin Corporation is focused on advancing cardiovascular disease management and increasing scientific understanding of cardiovascular risk beyond traditional therapies [5] - Vianex S.A., a leading Greek pharmaceutical company, has a 100-year history in the industry and is known for its strong commercial capabilities and expertise in cardiology [6][7]